· Published by Health Canada · Official notice
This is duplicated text of a letter from Apotex Incorporated, Dominion Pharmacal, Jamp Pharma Corporation, Marcan Pharmaceuticals Inc., Mylan Pharmaceuticals ULC, Pharmascience Inc., Pro Doc Limitée, Ranbaxy Pharmaceuticals Inc., Sanis Health Inc., Sivem Pharmaceuticals ULC and Teva Canada Limited and ratiopharm Inc. Contact the companies for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
January 20, 2015
Subject: Domperidone maleate associated with serious abnormal heart rhythms and sudden death (cardiac arrest)
The manufacturers of domperidone in collaboration with Health Canada would like to inform you of additional safety information for domperidone concerning a small increased risk of abnormal heart rhythms and sudden death (cardiac arrest).
Domperidone is a medication used to treat symptoms of slowed stomach emptying and stomach inflammation. Domperidone is also used to prevent symptoms such as nausea and vomiting caused by some drugs used to treat Parkinson's disease.
This safety information is for patients taking domperidone for any condition. It is important for you to be aware of the following information:
Changes to the electrical activity of the heart called QT prolongation can cause abnormal heart rhythms. These can be serious or life-threatening.
Domperidone should be used at the lowest effective dose for the shortest time possible. The maximum recommended dose is 30 mg a day (one 10 mg tablet three times a day). If you are already taking domperidone, contact your health care professional to find out if you are taking the correct dose for you.
Before starting treatment with domperidone, tell your doctor if you have or had any heart problems, low blood levels of potassium or magnesium, liver disease or if you are taking other medications, including medications without a prescription or natural health products.
Domperidone is also called domperidone maleate or:
The manufacturers of all domperidone products are changing the prescribing information (called Product Monograph) for domperidone to include this safety information about serious abnormal heart rhythms and sudden cardiac arrest.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious abnormal heart rhythms or sudden cardiac arrest, or other serious or unexpected side effects in patients receiving domperidone should be reported to the manufacturer (see the attached list) or Health Canada.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Yours sincerely,
original signed by:
Colin D'Cunha, MBBS, MHSc, FRCPC
Director, Global Medical Affairs,
Apotex Inc.
Len Neirinck, Ph.D.
Vice-President and Chief Scientific Officer,
Scientific Affairs,
Pharmascience Inc. and Dominion Pharmacal Inc.
Nathalie Toutant
Vice-president, Scientific Affairs
Jamp Pharma Corporation
Sudheer Paladugu, M.Pharm
Vice President - Technical
Marcan Pharmaceuticals Inc.,
Joanne Manley
Director Regulatory Affairs
Mylan Pharmaceuticals ULC
Jovette Deschênes
Director,
QC/QA, Regulatory Affairs
Pro Doc Limitée
Sukhvir Hundal
Director Regulatory Affairs
Ranbaxy Pharmaceuticals Canada Inc.
Paul Bonnici
Director Regulatory Affairs/QA
Sanis Health Inc
Fraidianie Sévigné
Director, Regulatory Affairs and Quality
Sivem Pharmaceuticals ULC
Bruce Valliant
Director, Medical Affairs
Teva Canada Limited